These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25425179)

  • 1. Synthesis of evidence for reimbursement decisions: a Bayesian reanalysis.
    Woertman W; Sluiter R; van der Wilt GJ
    Int J Technol Assess Health Care; 2014 Oct; 30(4):438-45. PubMed ID: 25425179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence based policy decisions through a Bayesian approach: the case of a statin appraisal in The Netherlands.
    Woertman W; Vermeulen B; Groenewoud H; van der Wilt GJ
    Health Policy; 2013 Oct; 112(3):234-40. PubMed ID: 23920344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Bayesian methods make data and analyses more relevant to decision makers? A perspective from Medicare.
    Sheingold SH
    Int J Technol Assess Health Care; 2001; 17(1):114-22. PubMed ID: 11329838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the effectiveness of HPV vaccination in the open population: a Bayesian approach.
    Woertman W; van der Wilt GJ
    Value Health; 2013 Jun; 16(4):604-9. PubMed ID: 23796295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
    Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
    Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classic or Bayesian research design and analysis. Does it make a difference?
    Bloom BS; de Pouvourville N; Libert S
    Int J Technol Assess Health Care; 2002; 18(1):120-6. PubMed ID: 11987435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bayesian Approach to Decision Making and Analysis in Nutrition Research and Practice.
    Gleason PM; Harris JE
    J Acad Nutr Diet; 2019 Dec; 119(12):1993-2003. PubMed ID: 31585828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policy relevance of Bayesian statistics overestimated?
    van der Wilt GJ; Rovers M; Straatman H; van der Bij S; van den Broek P; Zielhuis G
    Int J Technol Assess Health Care; 2004; 20(4):488-92. PubMed ID: 15609800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prioritisation by physicians in the Netherlands--the growth hormone example in drug reimbursement decisions.
    de Bont A; Zandwijken G; Stolk E; Niessen L
    Health Policy; 2007 Mar; 80(3):369-77. PubMed ID: 16684580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.
    Cerri KH; Knapp M; Fernandez JL
    Eur J Health Econ; 2014 Sep; 15(7):681-95. PubMed ID: 23864365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
    Koopmanschap MA; Stolk EA; Koolman X
    Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian hierarchical model for mortality data from cluster-sampling household surveys in humanitarian crises.
    Heudtlass P; Guha-Sapir D; Speybroeck N
    Int J Epidemiol; 2018 Aug; 47(4):1255-1263. PubMed ID: 29860332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian approach to evaluating net clinical benefit allowed for parameter uncertainty.
    Sutton AJ; Cooper NJ; Abrams KR; Lambert PC; Jones DR
    J Clin Epidemiol; 2005 Jan; 58(1):26-40. PubMed ID: 15649668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-compliance on the part of the professional community with a national guideline: an argumentative policy analysis.
    Moret-Hartman M; Knoester PD; Hekster YA; van der Wilt GJ
    Health Policy; 2006 Oct; 78(2-3):353-9. PubMed ID: 16387386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do drug policy makers access research evidence?
    Ritter A
    Int J Drug Policy; 2009 Jan; 20(1):70-5. PubMed ID: 18226519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.